Canopy Growth Narrows Focus Ahead of Earnings: Medical Margins and US Policy Shift in Sight

Analysts expect C$79M revenue as Canopy Growth reports Q4 results May 29. Focus on medical segment margins, cost discipline for positive EBITDA, and US Schedule III catalyst.

When Canopy Growth delivers its fourth-quarter results on May 29, the market will be looking beyond headline revenue for signs that its turnaround strategy is taking hold. Analysts expect sales of roughly C$79 million for the period, a sequential and year-over-year increase, but the real test lies in how the company’s core segments are performing under chief executive Luc Mongeau’s cost-conscious overhaul.

The cannabis producer currently carries a market value of around C$635 million on the Toronto Stock Exchange and US$512 million on the Nasdaq, where shares closed at US$1.11 last week. In Toronto, the stock settled at C$1.54 on Friday, down slightly on the day, as trading volumes stayed within normal ranges ahead of the print. Technical analysts are watching the historical low of C$1.18 closely, while the psychological C$1.50 mark remains a key level.

Medical Cannabis Takes the Lead

Canopy Growth is leaning heavily on its medical franchise, Spectrum Therapeutics, as a source of reliable margins. New softgel capsules have been introduced to give patients more flexible dosing, a move designed to lock in steady revenue from a segment that has consistently outperformed the volatile recreational market. The medical business recently posted double-digit revenue growth, and the company expects it to remain a cornerstone of profitability as it tightens its supply chains in Germany and Australia.

“The medical side offers dependable gross margins,” one strategist noted, “and the product refresh is intended to sustain that edge.”

US Expansion on Hold but Ready

Stateside, the company continues to consolidate its interests through the Canopy USA structure, which now houses Acreage Holdings, Wana Brands and Jetty Extracts. The acquisitions are complete, and management has built a unified platform across key US markets with a light capital footprint. Debt reduction remains a priority, and the balance sheet is described as well-funded, partly thanks to the integration of MTL Cannabis in Canada.

The real catalyst for this US portfolio, however, depends on federal reform. A Department of Justice proposal to reclassify cannabis from Schedule I to Schedule III — signalled by a 2025 decree — is still awaiting concrete implementation. For Canopy, a softer regulatory environment would slash tax burdens and open the door to institutional investment, but for now the timeline remains uncertain.

Cost Discipline and the Path to Positive EBITDA

Across all operations, Mongeau’s asset-light strategy is the engine of the turnaround. The goal is to drive down net losses and reach a positive adjusted EBITDA, a milestone the company has set as a clear target. The quarterly numbers due on May 29 will show whether the cost cuts are translating into operational progress, particularly in Canada’s medical segment and the international operations.

Cautious Outlook From Analysts

Given the mix of operational progress and regulatory uncertainty, Wall Street has adopted a wait-and-see stance. The consensus rating on Canopy Growth is “Hold,” with most experts preferring to see sustained improvement before upgrading the stock. For now, the shares trade in a narrowing range, and the upcoming earnings report will be the next major test of whether the company’s disciplined approach can finally begin to rebuild investor confidence.